MLYS

Mineralys Therapeutics Inc

18.18

Oct 30 • 3:59 PM ET -3.06 (-14.41%)

18.33

Aftermarket • 7:57 PM ET +0.15 (0.83%)

Healthcare Biotechnology USA Small NASD

Peers: NAMS ALNY AZN MAZE VERA ARDX CYTK ARWR MIST AKBA

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FESM DFAS

Scroll to Statements

Index	RUT
Market Cap	1.61B
Enterprise Value	1.04B
Income	-349.58M
Sales	0.00M
Book/sh	6.24
Cash/sh	7.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Feb 10, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.92
P/C	2.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	34.46
Current Ratio	34.46
Debt/Eq	0.18
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	-4.24
EPS next Y	-2.43
EPS next Q	-0.55
EPS this Y	-95.79%
EPS next Y	45.81%
EPS next 5Y	17.66%
EPS past 3/5Y	-46.34% -101.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	-19.00%
Sales Y/Y TTM	-
EPS Q/Q	-330.32%
Sales Q/Q	-
Earnings	Nov 04 AMC
EPS/Sales Surpr.	-419.50% -

Insider Own	31.19%
Insider Trans	-1.67%
Inst Own	89.17%
Inst Trans	12.19%
ROA	-69.67%
ROE	-80.88%
ROIC	-53.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.87%
SMA50	-26.62%
SMA200	-32.65%
Trades

Shs Outstand	88.35M
Shs Float	60.84M
Short Float	12.23%
Short Ratio	6.13
Short Interest	7.44M
52W High	47.65 -61.85%
52W Low	20.12 -9.64%
Volatility	7.16% 6.04%
ATR (14)	1.38
RSI (14)	29.89
Beta	0.71
Rel Volume	3.28
Avg Volume	1.21M
Volume	3,979,277

Perf Week	-11.53%
Perf Month	-23.36%
Perf Quarter	-29.48%
Perf Half Y	-37.87%
Perf YTD	-49.90%
Perf Year	-55.79%
Perf 3Y	125.28%
Perf 5Y	-
Perf 10Y	-
Recom	1.40
Target Price	45.22
Prev Close	21.24
Price	18.18
Change %	-14.41%

Consensus

Strong Buy

Avg. Price Target

$45.22

Implied Upside

+148.7%

Analysts11incl. previous ratings

Rating Distribution9 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Neutral	$29	+59.5%
Apr 27, 2026	Initiated	TTD Cowen	Buy
Jun 11, 2025	Initiated	JJefferies	Hold	$15	-17.5%
Jul 10, 2024	Initiated	HH.C. Wainwright	Buy	$30	+65.0%
Apr 02, 2024	Initiated	GGoldman	Buy	$30	+65.0%
Mar 07, 2023	Initiated	WWells Fargo	Overweight	$27	+48.5%
Mar 07, 2023	Initiated	SStifel	Buy	$45	+147.5%
Mar 07, 2023	Initiated	GGuggenheim	Buy	$32	+76.0%
Mar 07, 2023	Initiated	EEvercore ISI	Outperform
Mar 07, 2023	Initiated	CCredit Suisse	Outperform	$40	+120.0%
Mar 07, 2023	Initiated	BBofA Securities	Buy	$39	+114.5%

Oct-28-26 09:49PM	Mineralys Heads Into Final Pre-PDUFA Report With Launch Readiness And Cash Burn In Focus (Earnings Whispers)
04:05PM	Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026 (GlobeNewswire)
07:05AM	Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International (GlobeNewswire)
Oct-22-26 06:40PM	Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 (GlobeNewswire)
Oct-19-26 04:05PM	Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats (GlobeNewswire)
09:00AM	Loading…
Oct-09-26 09:00AM	Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire)
Oct-02-26 04:30PM	Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 (GlobeNewswire)
Oct-01-26 04:05PM	Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire) -5.61%
Sep-29-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-26 04:05PM	Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-23-26 04:05PM	Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 (GlobeNewswire) -8.54%
Sep-21-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-26 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-13-26 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:01AM	Loading…
Aug-12-26 01:01AM	Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-26 04:05PM	Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-26 08:00AM	Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 (GlobeNewswire)
Jul-27-26 04:01PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-26 10:00AM	Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-08-26 04:05PM	Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -5.02% +7.47%
07:00AM	Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-03-26 06:05AM	Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) -13.14%
06:00AM	Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing (GlobeNewswire)
May-30-26 11:15AM	Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-27-26 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-18-26 04:05PM	Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-06-26 04:05PM	Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-26 05:34PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
04:05PM	Loading…
Apr-29-26 04:05PM	Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +15.23%
Mar-24-26 08:00AM	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer (GlobeNewswire)
Mar-16-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 11:06PM	Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 04:30PM	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 (GlobeNewswire)
Feb-26-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 07:00PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Jan-30-26 12:24AM	Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones (Insider Monkey)
Jan-06-26 08:00AM	Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rodman David Malcom	Officer	Oct 13 '26	Proposed Sale	22.04	3,542	78,066		Oct 13 04:11 PM
Congleton Jon	Chief Executive Officer	Sep 30 '26	Sale	25.46	75,000	1,909,665	528,621	Oct 02 05:53 PM
Congleton Jon	Officer	Sep 30 '26	Proposed Sale	25.46	75,000	1,909,662		Sep 30 04:07 PM
Slingsby Brian Taylor	Director	Sep 22 '26	Sale	28.81	104,320	3,005,303	7,805,718	Sep 24 09:49 PM
Warren Eric	Chief Commercial Officer	Sep 21 '26	Option Exercise	13.24	7,438	98,479	45,838	Sep 22 06:48 PM
Warren Eric	Chief Commercial Officer	Sep 21 '26	Sale	28.12	7,438	209,136	38,400	Sep 22 06:48 PM
CATALYS PACIFIC FUND LP	Director	Sep 22 '26	Proposed Sale	28.81	104,320	3,005,303		Sep 22 04:09 PM
Warren Eric	Officer	Sep 21 '26	Proposed Sale	28.12	7,438	209,135		Sep 21 04:05 PM
Karydas Daphne	Director	Sep 15 '26	Option Exercise	12.02	3,000	36,060	9,200	Sep 17 05:41 PM
Karydas Daphne	Director	Sep 15 '26	Sale	28.58	3,000	85,740	6,200	Sep 17 05:41 PM
Rodman David Malcom	Officer	Sep 17 '26	Proposed Sale	27.95	417	11,655		Sep 17 04:06 PM
Karydas Daphne	Officer	Sep 15 '26	Proposed Sale	28.58	3,000	85,740		Sep 15 04:19 PM
Rodman David Malcom	Officer	Sep 14 '26	Proposed Sale	28.14	7,709	216,931		Sep 14 04:06 PM
Rodman David Malcom	Officer	Sep 09 '26	Proposed Sale	30.87	2,171	67,019		Sep 09 04:05 PM
Warren Eric	Chief Commercial Officer	Aug 21 '26	Option Exercise	13.24	7,437	98,466	45,837	Aug 25 05:16 PM
Warren Eric	Chief Commercial Officer	Aug 21 '26	Sale	25.98	7,437	193,189	38,400	Aug 25 05:16 PM
Warren Eric	Officer	Aug 21 '26	Proposed Sale	25.98	7,437	193,188		Aug 21 04:14 PM
Rodman David Malcom	Officer	Aug 17 '26	Proposed Sale	25.46	417	10,617		Aug 17 04:38 PM
Rodman David Malcom	Officer	Aug 13 '26	Proposed Sale	26.48	14,056	372,187		Aug 13 04:12 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '26	Option Exercise	16.00	2,170	34,720	53,554	Aug 12 07:33 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '26	Sale	27.09	2,170	58,785	51,384	Aug 12 07:33 PM
Rodman David Malcom	Officer	Aug 10 '26	Proposed Sale	27.09	2,170	58,785		Aug 10 04:39 PM
Warren Eric	Chief Commercial Officer	Jul 21 '26	Option Exercise	13.24	7,438	98,479	45,838	Jul 23 06:39 PM
Warren Eric	Chief Commercial Officer	Jul 21 '26	Sale	26.87	7,438	199,885	38,400	Jul 23 06:39 PM
Warren Eric	Officer	Jul 21 '26	Proposed Sale	26.87	7,438	199,885		Jul 21 04:11 PM
Rodman David Malcom	Chief Medical Officer	Jul 17 '26	Option Exercise	15.44	416	6,423	51,800	Jul 20 09:00 PM
Rodman David Malcom	Chief Medical Officer	Jul 17 '26	Sale	26.53	416	11,036	51,384	Jul 20 09:00 PM
Rodman David Malcom	Officer	Jul 17 '26	Proposed Sale	26.48	416	11,016		Jul 17 04:03 PM
Congleton Jon	Chief Executive Officer	Jul 13 '26	Sale	27.24	10,700	291,441	603,621	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 13 '26	Option Exercise	7.28	14,058	102,365	71,791	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 13 '26	Sale	27.58	14,058	387,717	57,733	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 15 '26	Sale	26.61	6,349	168,955	51,384	Jul 15 08:58 PM
Rodman David Malcom	Officer	Jul 15 '26	Proposed Sale	26.61	6,349	168,955		Jul 15 04:13 PM
Congleton Jon	Officer	Jul 13 '26	Proposed Sale	27.24	10,700	291,441		Jul 13 04:23 PM
Rodman David Malcom	Officer	Jul 13 '26	Proposed Sale	26.72	14,508	387,717		Jul 13 04:22 PM
Rodman David Malcom	Chief Medical Officer	Jul 09 '26	Option Exercise	16.00	2,171	34,736	59,904	Jul 10 07:15 PM
Rodman David Malcom	Chief Medical Officer	Jul 09 '26	Sale	30.30	2,171	65,781	57,733	Jul 10 07:15 PM
Rodman David Malcom	Officer	Jul 09 '26	Proposed Sale	30.30	2,171	65,781		Jul 09 04:10 PM
Congleton Jon	Chief Executive Officer	Jun 30 '26	Sale	26.14	75,000	1,960,601	614,321	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Option Exercise	13.24	104,124	1,378,602	142,524	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Sale	25.90	104,124	2,696,322	38,400	Jun 30 06:41 PM
Congleton Jon	Officer	Jun 30 '26	Proposed Sale	26.14	75,000	1,960,602		Jun 30 04:20 PM
Warren Eric	Officer	Jun 26 '26	Proposed Sale	25.90	104,124	2,696,322		Jun 29 09:05 AM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Option Exercise	14.36	4,584	65,818	61,679	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Option Exercise	10.20	3,542	36,128	66,985	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Sale	23.81	9,890	235,487	57,095	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Sale	25.00	4,584	114,600	57,095	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Option Exercise	12.02	3,000	36,060	9,200	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Sale	25.00	3,000	75,000	6,200	Jun 17 09:18 PM
Rodman David Malcom	Officer	Jun 17 '26	Proposed Sale	25.00	4,584	114,600		Jun 17 04:20 PM
Karydas Daphne	Officer	Jun 17 '26	Proposed Sale	25.00	3,000	75,000		Jun 17 04:15 PM
Rodman David Malcom	Officer	Jun 15 '26	Proposed Sale	23.81	9,890	235,487		Jun 15 04:58 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Option Exercise	16.00	2,170	34,720	65,613	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Option Exercise	1.08	6,349	6,857	69,792	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Sale	23.93	6,349	151,901	63,443	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Sale	25.00	2,170	54,250	63,443	Jun 12 06:04 PM
Rodman David Malcom	Officer	Jun 12 '26	Proposed Sale	23.93	6,349	151,901		Jun 12 04:17 PM
Rodman David Malcom	Officer	Jun 10 '26	Proposed Sale	25.00	2,170	54,250		Jun 10 04:11 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Option Exercise	15.44	417	6,438	63,860	May 19 07:15 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Sale	27.55	417	11,488	63,443	May 19 07:15 PM
Rodman David Malcom	Officer	May 18 '26	Proposed Sale	27.55	417	11,488		May 18 04:10 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Option Exercise	12.39	7,707	95,484	77,499	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Option Exercise	16.00	2,171	34,736	71,963	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Option Exercise	1.08	6,348	6,856	76,140	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Sale	28.58	14,056	401,789	63,443	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Sale	29.36	6,348	186,348	69,792	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Sale	29.71	2,171	64,500	69,792	May 13 09:42 PM
Rodman David Malcom	Officer	May 13 '26	Proposed Sale	28.58	14,056	401,790		May 13 04:11 PM
Rodman David Malcom	Officer	May 12 '26	Proposed Sale	29.36	6,348	186,348		May 12 05:05 PM
Rodman David Malcom	Officer	May 11 '26	Proposed Sale	29.71	2,171	64,500		May 11 04:27 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Option Exercise	15.44	416	6,423	70,208	Apr 21 06:59 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Sale	31.33	416	13,033	69,792	Apr 21 06:59 PM
Rodman David Malcom	Officer	Apr 17 '26	Proposed Sale	31.33	416	13,033		Apr 17 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Option Exercise	7.28	14,058	102,365	90,198	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Sale	26.54	14,058	373,087	76,140	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 15 '26	Sale	27.66	6,348	175,586	69,792	Apr 15 09:45 PM
Congleton Jon	Chief Executive Officer	Apr 13 '26	Sale	26.83	15,730	421,979	689,321	Apr 15 09:45 PM
Rodman David Malcom	Officer	Apr 15 '26	Proposed Sale	27.66	6,348	175,586		Apr 15 04:21 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Option Exercise	16.00	2,170	34,720	78,310	Apr 13 09:13 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Sale	27.38	2,170	59,415	76,140	Apr 13 09:13 PM
Congleton Jon	Officer	Apr 13 '26	Proposed Sale	26.83	15,730	421,980		Apr 13 04:22 PM
Rodman David Malcom	Officer	Apr 13 '26	Proposed Sale	26.54	14,058	373,087		Apr 13 04:18 PM
Rodman David Malcom	Officer	Apr 09 '26	Proposed Sale	27.38	2,170	59,415		Apr 09 04:24 PM
Congleton Jon	Chief Executive Officer	Mar 31 '26	Sale	26.27	75,000	1,970,522	705,051	Apr 02 06:54 PM
Karydas Daphne	Director	Mar 31 '26	Option Exercise	12.02	3,000	36,060	9,200	Apr 02 06:53 PM
Karydas Daphne	Director	Mar 31 '26	Sale	25.00	3,000	75,000	6,200	Apr 02 06:53 PM
Karydas Daphne	Officer	Mar 31 '26	Proposed Sale	25.00	3,000	75,000		Mar 31 04:18 PM
Congleton Jon	Officer	Mar 31 '26	Proposed Sale	26.27	75,000	1,970,521		Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '26	Buy	23.67	310,700	7,354,269	5,767,221	Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 30 '26	Buy	24.16	58,300	1,408,528	5,825,521	Mar 31 04:15 PM
Rodman David Malcom	Officer	Mar 17 '26	Proposed Sale	25.65	417	10,696		Mar 17 05:04 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Option Exercise	15.44	417	6,438	76,557	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Sale	25.65	417	10,696	76,140	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Option Exercise	12.39	7,709	95,508	90,198	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Option Exercise	1.08	6,348	6,856	88,837	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Sale	26.26	14,058	369,225	76,140	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Sale	27.37	6,348	173,748	82,489	Mar 16 05:20 PM
Rodman David Malcom	Officer	Mar 13 '26	Proposed Sale	26.26	14,058	369,225		Mar 13 04:50 PM
Rodman David Malcom	Officer	Mar 12 '26	Proposed Sale	27.37	6,348	173,748		Mar 12 04:13 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Option Exercise	16.00	2,171	34,736	84,660	Mar 10 05:48 PM

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

PresidentDr. Jon Congleton

M.P.H.Dr. Brian Taylor Slingsby M.D.

CFO & SecretaryMr. Adam Scott Levy

Chief Legal OfficerMr. Jeffrey A. Munsie J.D.

Senior Vice President of CMCDr. Robert McKean Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLYS

Mineralys Therapeutics Inc

Upgrade your Finviz experience